RxDoctor Payments Data

Susan Sarabia

Family · Sun City West, AZNPI 1538606439

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,604 of the $2,234 with a category attached, or 71.8%. Intuitive Surgical accounts for 71.8% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2023 at $1,723 and has fallen 98.2% since, to $32 in 2025.

$2,234in general payments, 2019–2025

Across 32 payments — averaging $69.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$2K
  • Novo Nordisk$168
  • AbbVie$86
  • Pfizer$84
  • Lilly USA, LLC$83
  • Abbott$78
  • plus $132 from 6 others
$112,143in research payments, 2019–2025

Across 7 payments — averaging $16,020 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Intuitive Surgical Operations, Inc.$112K

What the payments were for

  • Travel & lodging$1,60472%
  • Food & beverage$63028%

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,234 in reported general payments places this provider in the 80th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$64,611
Medicare patients
383
Services billed
976

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide49$59,357
Atorvastatin Calcium174$1,541
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,405
Levothyroxine Sodium162$1,131
Gabapentin61$1,001
Omeprazole88$988
Naproxen11$875
Losartan Potassium96$737
Rosuvastatin Calcium81$712
Trazodone Hcl67$697
Lisinopril129$665
SynthroidLevothyroxine Sodium13$644
Amlodipine Besylate107$583
Simvastatin62$577
Tamsulosin Hcl37$507

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$168$59,35749 claims
AbbVieSynthroid$86$64413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,119 family providers in Arizona.

Other family in Sun City West

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →